10.6084/m9.figshare.5568400
Keisuke Kurimoto
Keisuke
Kurimoto
Masamichi Hayashi
Masamichi
Hayashi
Rafael Guerrero-Preston
Rafael
Guerrero-Preston
Masahiko Koike
Masahiko
Koike
Mitsuro Kanda
Mitsuro
Kanda
Sho Hirabayashi
Sho
Hirabayashi
Hiroshi Tanabe
Hiroshi
Tanabe
Nao Takano
Nao
Takano
Naoki Iwata
Naoki
Iwata
Yukiko Niwa
Yukiko
Niwa
Hideki Takami
Hideki
Takami
Daisuke Kobayashi
Daisuke
Kobayashi
Chie Tanaka
Chie
Tanaka
Suguru Yamada
Suguru
Yamada
Goro Nakayama
Goro
Nakayama
Hiroyuki Sugimoto
Hiroyuki
Sugimoto
Tsutomu Fujii
Tsutomu
Fujii
Michitaka Fujiwara
Michitaka
Fujiwara
Yasuhiro Kodera
Yasuhiro
Kodera
<i>PAX5</i> gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma
Taylor & Francis Group
2017
CDDP
esophageal cancer
GLUT1
methylation
PAX5
2017-11-27 12:57:00
Dataset
https://tandf.figshare.com/articles/dataset/_i_PAX5_i_gene_as_a_novel_methylation_marker_that_predicts_both_clinical_outcome_and_cisplatin_sensitivity_in_esophageal_squamous_cell_carcinoma/5568400
<p>Therapeutic strategies for esophageal cancer largely depend on histopathological assessment. To select appropriate treatments of individual patients, we examined the background molecular characteristics of tumor malignancy and sensitivity to multidisciplinary therapy. Seventy-eight surgically-resected esophageal squamous cell carcinoma (ESCC) cases during 2001–2013 were examined. <i>PAX5</i>, a novel gene methylation marker in ESCC, was evaluated in the specimens, as methylation of this gene was identified as an extremely tumor-specific event in squamous cell carcinogenesis of head and neck. <i>PAX5</i> methylation status was evaluated by quantitative MSP (QMSP) assays. Mean QMSP value was 15.7 (0–136.3) in ESCCs and 0.3 (0–8.6) in adjacent normal tissues (<i>P</i> < 0.001). The 78 cases were divided into high QMSP value (high QMSP, n = 26) and low QMSP value (low QMSP, n = 52). High QMSP cases were significantly associated with downregulated <i>PAX5</i> expression (<i>P</i> = 0.040), and showed significantly poor recurrence-free survival [Hazard Ratio (HR) = 2.84; <i>P</i> = 0.005; 95% Confidence Interval (CI): 1.39–5.81] and overall survival (HR = 3.23; <i>P</i> = 0.002; 95%CI: 1.52–7.01) in multivariable analyses with histopathological factors. PAX5-knockdown cells exhibited significantly increased cell proliferation and cisplatin resistance. <i>PAX5</i> gene methylation can predict poor survival outcomes and cisplatin sensitivity in ESCCs and could be a useful diagnostic tool for cancer therapy selection.</p>